Xinjiang Medical University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Urumqi China (1956)

Organization Overview

First Clinical Trial
2007
NCT00548223
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cancer Hospital Affiliated to Xinjiang Medical University | Cancer Hospital of Xinjiang Medical University | Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC | Cnacer Hospital of Xinjiang Medical University | First Affiliated Hospital of Xinjiang Medical University | Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region | People's Hospital of Xinjiang Uygur Autonomous Region | Tang Xushan | The Affiliated Tumor Hospital of Xinjiang Medical University | The First Teaching Hospital of Xinjiang Medical University | The Sixth People's Hospital of Xinjiang | Third Affiliated Hospital of Xinjiang Medical University | Xinjiang Medical University | Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine | Xinjiang Uygur Autonomous Region People's Hospital | Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital

Active Ingredients

Drugs in Phase 4 Trials (18)

berberine (1 trial)

cisatracurium (nimbex) (1 trial)

deng zhan sheng mai (1 trial)

ethambutol (myambutol) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

isoniazid (nydrazid) (1 trial)

lamivudine (epivir) (1 trial)

levofloxacin (levaquin) (1 trial)

lopinavir (Kaletra) (2 trials)

nevirapine (viramune) (1 trial)

prednisone (meticorten) (2 trials)

pyrazinamide (Aldinamide) (1 trial)

rifampin (1 trial)

ritonavir (Norvir) (1 trial)

rocuronium (zemuron) (1 trial)

urea (1 trial)

vecuronium (norcuron) (1 trial)

zidovudine (retrovir) (1 trial)

Drugs in Phase 3 Trials (22)

alpha-lipoic acid (1 trial)

anlotinib (1 trial)

carboplatin (paraplatin) (1 trial)

cinobufacin (1 trial)

cisplatin (platinol) (2 trials)

cyclophosphamide (cytoxan) (1 trial)

cyclosporine (sandimmune) (1 trial)

docetaxel (taxotere) (2 trials)

endostatin (endostar) (3 trials)

epirubicin (ellence) (2 trials)

erlotinib (tarceva) (1 trial)

gelatin (1 trial)

gemcitabine (gemzar) (2 trials)

gimeracil (1 trial)

levamisole (ergamisol) (1 trial)

lipiodol (1 trial)

nedaplatin (1 trial)

oteracil (1 trial)

oxaliplatin (eloxatin) (1 trial)

pemetrexed (alimta) (1 trial)

rituximab (rituxan) (2 trials)

vincristine (oncovin) (1 trial)

Drugs in Phase 2 Trials (3)

capecitabine (xeloda) (1 trial)

etoposide (vepesid) (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 1 Trials (1)

autologous natural killer cells (1 trial)

Drugs in Other Trials (3)

hydroxychloroquine (plaquenil) (1 trial)

remifentanil (ultiva) (1 trial)

sodium bicarbonate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 4)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Cardiovascular Diseases (Phase 3)

Cholangiocarcinoma (Phase 3)

Coronavirus Infections (Phase 1)

Delayed Emergence from Anesthesia (Phase 4)

Fatty Liver (Phase 4)

Hepatitis B (Phase 4)

HIV Infections (Phase 4)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 4)

Obesity (Phase 3)

Pneumonia (Phase 1)

Postoperative Complications (Phase 4)

Purpura (Phase 4)

Purpura, Thrombocytopenic (Phase 4)

Purpura, Thrombocytopenic, Idiopathic (Phase 4)

Stomach Neoplasms (Phase 3)

Stroke (Phase 4)

Tuberculosis (Phase 4)

Tuberculosis, Pulmonary (Phase 4)

Uterine Cervical Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial APIs: 47